2. Metabolic Enzyme/Protease Immunology/Inflammation
  3. MMP NO Synthase
  4. KD014

KD014  (Synonyms: DX-2400; DX-2410)

Cat. No.: HY-P991316 Purity: 96.98%
COA
SDS
Technical Support

KD014 (DX-2400) is a human monoclonal antibody that selectively targets MMP‑14. KD014 inhibits collagen degradation and regulates the polarization of macrophages toward an anti-inflammatory/anti-tumor phenotype. KD014 alleviates joint damage in rheumatoid arthritis and suppresses tumor growth and invasion. KD014 can be used in studies related to breast cancer and rheumatoid arthritis.

For research use only. We do not sell to patients.

KD014

KD014 Chemical Structure

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

KD014 Related Antibodies

Top Publications Citing Use of Products

View All MMP Isoform Specific Products:

View All Isoforms
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

KD014 (DX-2400) is a human monoclonal antibody that selectively targets MMP‑14. KD014 inhibits collagen degradation and regulates the polarization of macrophages toward an anti-inflammatory/anti-tumor phenotype. KD014 alleviates joint damage in rheumatoid arthritis and suppresses tumor growth and invasion. KD014 can be used in studies related to breast cancer and rheumatoid arthritis[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target[3]

MMP14

0.9 nM (Ki)

In Vitro

KD014 (0.1-50 μg/mL; 3 days) has no effect on the viability of 4T1 or E0771 mouse breast cancer cells[1].
KD014 (0.2-100 μg/mL) significantly inhibits the invasive ability of 4T1 mouse breast cancer cells through type I collagen matrix in a dose-dependent manner[1].
KD014 (100-500 nM; 4 days) dose-dependently inhibits the degradation of collagen membranes by human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS)[2].
KD014 (100-500 nM; 4 weeks) dose-dependently inhibits the invasion of bovine nasal cartilage by human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

KD014 Related Antibodies

Cell Invasion Assay[1]

Cell Line: 4T1 murine breast carcinoma cells
Concentration: 0.2, 2.0, 20, 100 μg/mL
Incubation Time: /
Result: Inhibited 4T1 cell invasion through a collagen matrix in a dose-dependent manner.
Exhibited statistically significant inhibition at all tested concentrations (P = .0314 at 0.2 μg/mL to P = .0004 at 100 μg/mL).

Cell Invasion Assay[2]

Cell Line: human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS)
Concentration: 100 nM; 500 nM
Incubation Time: 4 weeks
Result: Inhibited the invasion of human RA FLS into bovine nasal cartilage explants in a dose-dependent manner, as shown by reduced presence of invading cells compared to control.
In Vivo

KD014 (10 mg/kg; i.p.; once every 48 hours; up to 10 injections) inhibits tumor growth in 4T1 and E0771 orthotopic breast cancer mouse models[1].
KD014 (20-40 mg/kg; i.p.; once every other day for 10 days) significantly inhibits articular cartilage degradation and blocks arthritis progression in a mouse collagen-induced arthritis model[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: nude mice (female, 6-8 weeks, orthotopic 4T1/E0771 breast cancer model)[1]
Dosage: 10 mg/kg
Administration: i.p.; every 48 hours; up to 10 injections
Result: Inhibited tumor growth.
Polarized macrophages to an antitumor M1‑like phenotype, elevated iNOS expression and tumor perfusion.
Reduced hypoxia, and synergizes with radiotherapy in murine orthotopic 4T1 and E0771 breast cancer models.
Animal Model: DBA/1 (male, 11-13 weeks old, collagen-induced arthritis model)[2]
Dosage: 20, 40 mg/kg
Administration: i.p.; every other day; 10 days
Result: Markedly reduced cartilage degradation and serum COMP levels, mitigated arthritis spread to unaffected joints, and had minimal effect on joint swelling and bone erosion.
Gene ID

4323  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

144.01 kDa

Appearance

Liquid

Color

Colorless to light yellow

SMILES

N/A
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

KD014 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KD014DX-2400 DX-2410KD 014KD-014DX2400DX 2400DX2410DX 2410DX-2410MMPNO SynthaseMatrix metalloproteinasesNitric oxide synthasesNOSrheumatoid arthritis fibroblast-like synoviocytesiNOStumor-associated macrophageTGFβtransforming growth factor βorthotopic murine breast tumor modelsinducible nitric oxide synthaseMMP14/MT1-MMPSMAD2/3matrix metalloproteinase 14Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
KD014
Cat. No.:
HY-P991316
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.